Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)
Bicara Therapeutics posted quarterly Research & Development of $100000.0 for Q1 2026, down 98.48% year-on-year from $6.6 million in Q1 2025, and down 99.7% on a QoQ basis from $33.0 million in Q4 2025.
Bicara Therapeutics (BCAX) has 4 years of Research & Development data on file, last reported at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 98.48% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $90.9 million (up 81.87% YoY), and the FY2025 full-year result was $125.1 million, up 125.79% from the prior year.
- Research & Development for Q1 2026 stood at $100000.0, down from $33.0 million in the prior quarter.
- Across five years, Research & Development topped out at $33.0 million in Q3 2025 and bottomed at $100000.0 in Q1 2026.
- The 4-year median for Research & Development is $12.0 million (2024), against an average of $15.5 million.
- The widest annual swing landed in 2025, when Research & Development jumped 181.94%; it then slumped 98.48% in 2026.
- A 4-year view of Research & Development shows it stood at $10.5 million in 2023, then rose by 11.46% to $11.7 million in 2024, then surged by 181.94% to $33.0 million in 2025, then slumped by 99.7% to $100000.0 in 2026.
- The last three Research & Development figures came in at $100000.0 (Q1 2026), $33.0 million (Q4 2025), and $33.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 33.00 Mn |
| Sep 30, 2025 | 33.00 Mn |
| Jun 30, 2025 | 24.80 Mn |
| Mar 31, 2025 | 6.58 Mn |
| Dec 31, 2024 | 11.70 Mn |
| Sep 30, 2024 | 15.90 Mn |
| Jun 30, 2024 | 15.80 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 10.50 Mn |
| Sep 30, 2023 | 6.90 Mn |